Hyperinsulinemia (Metabolic Disorder) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 85 Published: December 30, 2021 Report Code: GMDGDHC13199IDB

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue, and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise, and other lifestyle changes.

The Hyperinsulinemia Drugs in Development market research report provides an overview of the Hyperinsulinemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperinsulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects.

What are the targets of the Hyperinsulinemia pipeline drugs market?

The targets of the Hyperinsulinemia pipeline drugs market are Glucagon Receptor, Glucagon Like Peptide 1 Receptor, Somatostatin Receptor Type 5, Ganglioside GM1, and Insulin Receptor.

Hyperinsulinemia pipeline drugs market, by targets

Hyperinsulinemia pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Hyperinsulinemia pipeline drugs market?

The mechanisms of action of the Hyperinsulinemia pipeline drugs market are Glucagon Receptor Agonist, Glucagon Like Peptide 1 Receptor Antagonist, Somatostatin Receptor Type 5 Agonist, Ganglioside GM1 Replacement, and Insulin Receptor Antagonist.

Hyperinsulinemia pipeline drugs market, by mechanisms of action

Hyperinsulinemia pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Hyperinsulinemia pipeline drugs market?

The routes of administration in the Hyperinsulinemia pipeline drugs market are intravenous, subcutaneous, oral, and, intramuscular.

Hyperinsulinemia pipeline drugs market, by routes of administration

Hyperinsulinemia pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Hyperinsulinemia pipeline drugs market?

The molecule types in the Hyperinsulinemia pipeline drugs market are synthetic peptide, small molecule, monoclonal antibody, and recombinant peptide.

Hyperinsulinemia pipeline drugs market, by molecule types

Hyperinsulinemia pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Hyperinsulinemia pipeline drugs market?

Some of the key companies in the Hyperinsulinemia pipeline drugs market are Crinetics Pharmaceuticals Inc, AmideBio LLC, Eiger BioPharmaceuticals Inc, Hanmi Pharmaceuticals Co Ltd, PegBio Co Ltd, Rezolute Inc, Seneb BioSciences Inc, XERIS Pharmaceuticals Inc, and Zealand Pharma AS.

Hyperinsulinemia pipeline drugs market, by key companies

Hyperinsulinemia pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Glucagon Receptor, Glucagon Like Peptide 1 Receptor, Somatostatin Receptor Type 5, Ganglioside GM1, and Insulin Receptor
Mechanisms of Action Glucagon Receptor Agonist, Glucagon Like Peptide 1 Receptor Antagonist, Somatostatin Receptor Type 5 Agonist, Ganglioside GM1 Replacement, and Insulin Receptor Antagonist
Routes of Administration Intravenous, Subcutaneous, Oral, and Intramuscular
Molecule Types Synthetic Peptide, Small Molecule, Monoclonal Antibody, and Recombinant Peptide
Key Companies Crinetics Pharmaceuticals Inc, AmideBio LLC, Eiger BioPharmaceuticals Inc, Hanmi Pharmaceuticals Co Ltd, PegBio Co Ltd, Rezolute Inc, Seneb BioSciences Inc, XERIS Pharmaceuticals Inc, and Zealand Pharma AS

This report provides:

  • A snapshot of the global therapeutic landscape of Hyperinsulinemia.
  • Reviews of pipeline therapeutics for Hyperinsulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key players involved in Hyperinsulinemia therapeutics and enlists all their major and minor projects.
  • Assessment of Hyperinsulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Hyperinsulinemia.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Hyperinsulinemia.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Hyperinsulinemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Players

  • AmideBio LLC

    Crinetics Pharmaceuticals Inc

    Eiger BioPharmaceuticals Inc

    Hanmi Pharmaceuticals Co Ltd

    PegBio Co Ltd

    Rezolute Inc

    Seneb BioSciences Inc

    XERIS Pharmaceuticals Inc

    Zealand Pharma AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperinsulinemia – Overview

Hyperinsulinemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperinsulinemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperinsulinemia – Companies Involved in Therapeutics Development

AmideBio LLC

Crinetics Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

Hanmi Pharmaceuticals Co Ltd

PegBio Co Ltd

Rezolute Inc

Seneb BioSciences Inc

XERIS Pharmaceuticals Inc

Zealand Pharma AS

Hyperinsulinemia – Drug Profiles

Hyperinsulinemia – Dormant Projects

Hyperinsulinemia – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hyperinsulinemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hyperinsulinemia – Pipeline by AmideBio LLC, 2021

Hyperinsulinemia – Pipeline by Crinetics Pharmaceuticals Inc, 2021

Hyperinsulinemia – Pipeline by Eiger BioPharmaceuticals Inc, 2021

Hyperinsulinemia – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Hyperinsulinemia – Pipeline by PegBio Co Ltd, 2021

Hyperinsulinemia – Pipeline by Rezolute Inc, 2021

Hyperinsulinemia – Pipeline by Seneb BioSciences Inc, 2021

Hyperinsulinemia – Pipeline by XERIS Pharmaceuticals Inc, 2021

Hyperinsulinemia – Pipeline by Zealand Pharma AS, 2021

Hyperinsulinemia – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Hyperinsulinemia, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.